Page 128 - 《中国药房》2021年2期

[ 4 ] 唐惠林，门鹏，翟所迪.药物快速卫生技术评估方法及应 [17] LIMA AODL，BALLESTER VG，SÁNCHEZ JFS，et al.
用[J].临床药物治疗杂志，2016，14（2）：1-4. Cost-effectiveness and budget impact of treatment with
[ 5 ] 李幼平，喻佳洁，孙鑫.快速评估方法与流程的探索[J].中 evolocumab versus statins and ezetimibe for hypercholes-
国循证医学杂志，2014，14（5）：497-500. terolemia in Spain[J]. Rev Esp Cardiol：Engl Ed，2018，71
[ 6 ] 中国成人血脂异常防治指南修订联合委员.中国成人血 （12）：1027-1035.
脂异常防治指南：2016 年修订版[J].中国循环杂志， [18] LEE TC，KAOUACHE M，GROVER SA，et al. Evalua-
2016，31（10）：937-953. tion of the cost-effectiveness of evolocumab in the FOU-
[ 7 ] HAILEY D. Toward transparency in health technology as- RIER study：a Canadian analysis[J]. CMAJ Open，2018，6
sessment：a checklist for HTA reports[J]. Int J Technol As- （2）：E162-E167.
sess，2003，19（1）：1-7. [19] BORISSOV B，URBICH M，GEORGIEVA B.et al.Cost-
[ 8 ] 陶欢，杨乐天，平安，等.随机或非随机防治性研究系统评 effectiveness of evolocumab in treatment of heterozygous
价的质量评价工具 AMSTAR2 解读[J].中国循证医学杂 familial hypercholesterolaemia in Bulgaria：measuring
志，2018，18（1）：101-108. health benefit by effectively treated patient-years[J]. J Mark
[ 9 ] HUSEREAU D，DRUMMOND M，PETROU S，et al. Access Health Policy，2017. DOI：10.1080/20016689.
Consolidated health economic evaluation reporting stan- [20] FONAROW GC，KEECH AC，PEDERSEN TR，et al.
dards （CHEERS） statement[J]. Pharmaco Economics， Cost-effectiveness of evolocumab therapy for reducing
2013，31（5）：361-367. cardiovascular events in patients with atherosclerotic car-
[10] DICEMBRINI I，GIANNINI S，RAGGHIANTI B，et al. diovascular disease[J]. JAMA Cardiol，2017，2（10）：
1069-1078.
Effects of PCSK9 inhibitors on LDL cholesterol，cardio-
[21] VILLA G，LOTHGREN M，KUTIKOVA L，et al. Cost-ef-
vascular morbidity and all-cause mortality：a systematic
fectiveness of Evolocumab in patients with high cardiovas-
review and meta-analysis of randomized controlled trials
cular risk in Spain[J]. Clin Ther，2017，39（4）：771-786.
[J]. J Endocrinol Invest，2019，42（9）：1029-1039.
[22] GANDRA SR，VILLA G，FONAROW GC，et al. Cost-ef-
[11] TURGEON RD，TSUYUKI RT，GYENES GT，et al. Car-
fectiveness of LDL-C lowering with evolocumab in pa-
diovascular efficacy and safety of PCSK9 inhibitors：sys-
tients with high cardiovascular risk in the United States[J].
tematic review and meta-analysis including the odyssey
Clin Cardiol，2016，39（6）：313-320.
outcomes trial[J]. Can J Cardiol，2018，34（12）：1600-
[23] LANDMESER U，CHAPMAN MJ，STOCK JK，et al.
1605.
2017 Update of ESC/EAS task force on practical clinical
[12] ZHU Y，SHEN X，JIANG Q，et al. Effects of monoclonal
guidance for proprotein convertase subtilisin/kexin type 9
antibodies against PCSK9 on clinical cardiovascular
inhibition in patients with atherosclerotic cardiovascular
events：a meta-analysis of randomized controlled trials[J].
disease or in familial hypercholesterolaemia[J]. Eur Heart
Herz，2017，44（4）：336-346.
J，2018，39（14）：1131-1143.
[13] MAJID ES，SHEKOUFEH N，MARYAM G，et al. Does
[24] JELINGER PS，HANDELSMAN Y，ROSENBLIT PD，
evolocumab，as a PCSK9 inhibitor，ameliorate the lipid
et al. American Association of Clinical Endocrinologists
profile in familial hypercholesterolemia patients：a me-
and American College of Endocrinology guidelines for
ta-analysis of randomized controlled trials[J]. J Pharm
management of dyslipidemia and prevention of cardiovas-
Pharm Sci，2017. DOI：10.18433/J36C8N.
cular disease-executive summary complete appendix to
[14] CHENG C，SUN S，ZHOU Y，et al. Efficacy and safety of
guidelines available at http：//journals.aace.com[J]. En-
different doses of evolocumab in reducing low-density li- docr Pract，2017，23（4）：479-497.
poprotein cholesterol levels：a meta-analysis[J]. Biomed [25] GRUNDY SM，STONE NJ，BAILEY AL，et al. 2018
Rep，2016，5（5）：541-547.
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/
[15] ZHANG XL，ZHU QQ，ZHU L，et al. Safety and efficacy APhA/ASPC/NLA/PCNA guideline on the management
of anti-PCSK9 antibodies：a meta-analysis of 25 random- of blood cholesterol：a report of the American Colege of
ized，controlled trials[J]. BMC Med，2015. DOI：10.1186/ Cardiology/American Heart Asociation Task Force on clin-
s12916-015-0358-8. ical practice guidelines[J]. J Am Col Cardiol，2019，73
[16] FONAROW GC，HOUT BV，VILLA G，et al. Updated （24）：e285-e350.
cost-effectiveness analysis of evolocumab in patients with （收稿日期：2020-08-19 修回日期：2020-11-29）
very high-risk atherosclerotic cardiovascular disease[J]. （编辑：陈 宏）
JAMA Cardiol，2019，4（7）：691-695.

·246 · China Pharmacy 2021 Vol. 32 No. 2 中国药房 2021年第32卷第2期